Our findings suggest that PNO1 expression can be used as diagnostic/prognostic biomarker for HCC and inhibition of PNO1 expression by CRISPR/Cas9 technology can be a beneficial therapeutic strategy. Here, PNO1 is linked to hepatocellular carcinoma.